MEDI-575, now known as Tovetumab , represents a promising advancement in cancer therapy , targeting selectively the protein Molecule HGFR . Early clinical trials suggest this medicine exhibits favorable results, particularly in patients with multiple non-hematologic malignancies that display HGF . The action involves inhibiting HGF routes, leading